-
51.发明授权
公开(公告)号：KR101235675B1
公开(公告)日：2013-02-21
申请号：KR1020100109058
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: 본 발명은 p-자일렌셀레노시아네이트를 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품에 관한 것이다. 상기 조성물 또는 건강기능식품은 지방세포분화 저해 효능이 우수하다.
-
公开(公告)号：KR1020130007909A
公开(公告)日：2013-01-21
申请号：KR1020110068563
申请日：2011-07-11
Applicant: 주식회사디엔에이링크 , 한국식품연구원
CPC classification number: C12Q1/6883 , C12Q2600/118
Abstract: PURPOSE: A polynucleotide for effectively diagnosing a risk of developing metabolic syndrome is provided to identify an individual with changed risk. CONSTITUTION: A composition for diagnosing a risk of developing metabolic syndrome contains a polynucleotide for diagnosing the risk of developing metabolic syndrome of an individual with obesity. A microarray for diagnosing the risk of developing metabolic syndrome contains the polynucleotide. A kit for diagnosing the risk of developing metabolic syndrome contains the polynucleotide. A method for identifying an individual with obesity, who has changed risk comprises: a step of providing a nucleic acid sample isolated from the individual with obesity; and a step of determining a nucleotide of a SNP site of one or more polynucleotides selected from sequence numbers 1-4.
Abstract translation: 目的：提供有效诊断发生代谢综合征风险的多核苷酸，以识别具有变化风险的个体。 构成：用于诊断发展代谢综合征风险的组合物含有用于诊断发生肥胖个体代谢综合征风险的多核苷酸。 用于诊断发生代谢综合征风险的微阵列包含多核苷酸。 用于诊断发展代谢综合征风险的试剂盒含有多核苷酸。 具有改变风险的用于鉴定具有肥胖症的个体的方法包括：提供从个体与肥胖分离的核酸样品的步骤; 以及确定选自序列号1-4中的一个或多个多核苷酸的SNP位点的核苷酸的步骤。
-
公开(公告)号：KR101200671B1
公开(公告)日：2012-11-12
申请号：KR1020100077529
申请日：2010-08-11
Applicant: 한국식품연구원
IPC: A61K31/785 , A61K31/765 , A61K31/74 , A61P3/04
Abstract: 본 발명은 폴리감마글루탐산을 유효성분으로 함유하는 비만예방 및 치료용 조성물을 제공한다. 본 발명에 따른 비만예방 및 치료용 조성물은 약제학적 또는 식품조성물로서 지방세포의 분화를 억제하여 비만예방 및 치료에 탁월한 효과를 발휘한다.
-
公开(公告)号：KR1020120061019A
公开(公告)日：2012-06-12
申请号：KR1020100109063
申请日：2010-11-04
Applicant: 한국식품연구원
IPC: A61K31/198 , A61P3/04 , A61P3/06 , A61P3/10
Abstract: PURPOSE: A pharmaceutical composition and health functional food containing selenomethionine are provided to prevent and treat obesity and lipid-related metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic diseases contains selenomethionine as an active ingredient. The pharmaceutical composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, suppository, or sterilized injection solution. Selenomethionine suppresses differentiation of adipocyte. A health functional food contains selenomethionine as an active ingredient. The health functional food is used in the form of capsules, tablets, granules, powder, or beverage.
Abstract translation: 目的：提供含有硒代甲硫氨酸的药物组合物和保健功能食品，用于预防和治疗肥胖症和与脂质有关的代谢疾病。 构成：用于预防和治疗肥胖症和与脂质有关的代谢疾病的药物组合物含有硒代甲硫氨酸作为活性成分。 药物组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，栓剂或灭菌注射液的形式制备。 硒代甲硫氨酸抑制脂肪细胞的分化。 健康功能食品含有硒代甲硫氨酸作为活性成分。 保健功能食品以胶囊，片剂，颗粒，粉末或饮料的形式使用。
-
55.发明公开바이오케닌에이 또는 약리학적으로 허용되는 이의 염을 활성성분으로 함유하는 신생혈관생성과 관련된 질환의 치료용 조성물 无效用于治疗与包含生物素或其药学上接受的药物的血管生成相关的疾病的组合物
公开(公告)号：KR1020120029557A
公开(公告)日：2012-03-27
申请号：KR1020100091411
申请日：2010-09-17
Applicant: 한국식품연구원
IPC: A61K31/352 , A61K36/48 , A61P35/00 , A61P27/02
Abstract: PURPOSE: A composition containing biochanin A or pharmaceutically acceptable salt thereof for treating angiogenesis-associated diseases is provided to treat various diseases. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetetic retinopathy, rheumatic arthritis, psoriasis, inflammation, endometriosis, aging or hemandioma. A pharmaceutical composition for suppressing angiogenesis contains biochanin A or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract translation: 目的：提供含有角鲨他汀A或其药学上可接受的盐用于治疗血管生成相关疾病的组合物以治疗各种疾病。 构成：用于治疗血管生成相关疾病的组合物含有作为活性成分的角鲨他汀A或其药学上可接受的盐。 血管生成相关疾病是癌症，糖尿病性视网膜病变，风湿性关节炎，牛皮癣，炎症，子宫内膜异位症，衰老或血管瘤。 用于抑制血管发生的药物组合物含有作为活性成分的角鲨他汀A或其药学上可接受的盐。
-
Patent Agency Ranking56.发明公开
公开(公告)号：KR1020120015221A
公开(公告)日：2012-02-21
申请号：KR1020100077551
申请日：2010-08-11
Applicant: 한국식품연구원
Abstract: PURPOSE: A composition containign sesamol or pharmaceutically acceptable salt is provided to suppress angiogenesis and to treat cancer, diabetic retinopathy, rheumatic arthritis, and psoriasis. CONSTITUTION: A composition for treating angiogenesis-associated diseases contains sesemol or pharmaceutically acceptable salt thereof as an active ingredient. The angiogenesis-associated diseases are cancer, diabetic retinopaghy, rheumatic arthritis, psoriasis, inflammation, endometriosis, and hemandioma. The sesamol or pharmaceutically acceptable salt thereof is contained in 0.1-10 wt%.
Abstract translation: 目的：提供含有塞萨莫酚或药学上可接受的盐的组合物以抑制血管生成并治疗癌症，糖尿病性视网膜病变，风湿性关节炎和牛皮癣。 构成：用于治疗血管生成相关疾病的组合物含有作为有效成分的西昔莫或其药学上可接受的盐。 血管生成相关疾病是癌症，糖尿病视网膜病，风湿性关节炎，牛皮癣，炎症，子宫内膜异位症和血管瘤。 芝麻酚或其药学上可接受的盐含量为0.1-10重量％。
-
公开(公告)号：KR1020120015206A
公开(公告)日：2012-02-21
申请号：KR1020100077529
申请日：2010-08-11
Applicant: 한국식품연구원
IPC: A61K31/785 , A61K31/765 , A61K31/74 , A61P3/04
CPC classification number: A61K31/785 , A23L33/175 , A61K31/195 , A61K31/765 , Y10S514/909
Abstract: PURPOSE: A composition containing poly gamma glutamic acid for preventing and treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains poly gamma glutamic acid(PGA) as an active ingredient. The molecular weight of PGA is 100kDa to 15,000kDa. The composition is a pharmaceutical composition or food additive. The composition further contains pharmacologically acceptable carrier. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution.
Abstract translation: 目的：提供含有用于预防和治疗肥胖症的多聚谷氨酸的组合物，以抑制脂肪细胞的分化并激活AMPK（5'AMP激活的蛋白激酶）。 构成：用于预防和治疗肥胖症的组合物含有聚γ谷氨酸（PGA）作为活性成分。 PGA的分子量为100kDa至15,000kDa。 组合物是药物组合物或食品添加剂。 组合物还含有药理学上可接受的载体。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，外用，栓剂或灭菌注射液的形式制备。
-
公开(公告)号：KR102227938B1
公开(公告)日：2021-03-16
申请号：KR1020180071098
申请日：2018-06-20
Abstract: 본발명은골다공증예측방법에관한것으로, 보다상세하게는환자의뼈에있어서, 골절이발생할것으로예상되는라인을산출하고, 골재생정도를종합하여정확하게골다공증발생여부및 위치를산출하기위한골다공증예측방법에관한것이다. 본발명의구성은골다공증예측방법에있어서, i) 분석대상뼈의 CT를촬영하여골강도및 예상골절조건을산출하는단계; ii) 골생성마커를검출하여골재생정도를측정하는단계; iii) 개인차에따른상기골다공증가능성을판단하기위한개인별조건을입력하는단계; 및 iv) 상기골강도, 상기예상골절조건, 상기골재생정도및 상기개인별조건을종합하여골다공증가능성을예측하는단계를포함하는것을특징으로하는골다공증예측방법을제공한다.
-
公开(公告)号：KR101897770B1
公开(公告)日：2018-09-12
申请号：KR1020170134477
申请日：2017-10-17
Applicant: 한국식품연구원
IPC: A61K36/31 , A23L33/105
CPC classification number: A61K36/31 , A23L33/105 , A23V2002/00 , A23V2200/3262
Abstract: 본발명은무순추출물을포함하는이상지질혈증의예방또는치료용약학조성물에관한것으로, 본발명에따른조성물은혈중총 콜레스테롤, LDL(Low density lipoprotein) 콜레스테롤및 트리글리세라이드(Triglyceride)의양을유의하게저하시키고, HDL(High density lipoprotein) 콜레스테롤의양을유의하게증가시켜이상지질혈증의예방및 치료에우수한효능을보이며, 천연물질인무순추출물을유효성분으로함유하여장기간복용하여도부작용이적은장점이있다.
-
-
-
-
-
-
-
-
Search Results
72
records
(took 0.028 seconds)
